Published : 19 May 2020
Aagami has received an assignment from a French company developing a natural tobacco leaf extracted drug for smoking cessation. Only 2 injections for complete smoking cessation of people who want to quit.
While clinical trials are in progress in various regions, the client wanted to know the India regulatory path.
Aagami will be delivering this project along with Regulatory Expert Associate, which is a 36 years old organization & has provided regulatory consultancy services to various global blue chip as well as emerging pharmaceutical, nutraceutical, cosmeceutical, cosmetic and medical device companies, including Abbott, Adamas, Amgen, Astellas, Boston Scientific, CMIC, Dabur, Eisai, GSK, Guidant, Hisamitsu, Hoya, Johnson & Johnson, Menarini, MSD (Merck), Rohto, Sanofi-Aventis, Santen, Takeda, Teva, UCB, Unilever etc.
Based on the findings of the report, the client shall decide on India partnering/entry strategy, which Aagami specializes in and will take it up as a separate assignment.